Urologic Oncology: November 2 3, Advances in Clinical Practice. 7th. Nursing Session November 2, Urologic Oncology:

Transcription

1 7th Urologic Oncology: Advances in Clinical Practice November 2 3, 2012 MD Anderson, Dan L. Duncan Building Floor 8 Conference Center, 1155 Pressler, Houston, Texas Nursing Session November 2, 2012 Urologic Oncology: Nursing Advances in Clinical Practice MD Anderson, Mays Clinic, ACB Holcombe Boulevard, Houston, Texas

2 7th Urologic Oncology: Advances in Clinical Practice November 2-3, 2012 Nursing Session November 2, 2012 Urologic Oncology: Nursing Advances in Clinical Practice Focus The 7th Urologic Oncology Conference will focus on the diagnosis, treatment, clinical advances, and controversies in localized and advanced cancers of the bladder, prostate and kidney. Educational Objectives After attending the conference, participants should be able to illustrate and implement clinical advances in the diagnosis and evaluation of bladder, prostate, and kidney cancers (knowledge, competence, performance, patient outcomes); illustrate and implement clinical advances in the treatment approach to localized and locally advanced bladder, prostate and kidney cancers, including the role of minimally invasive robotic surgery (knowledge, competence, performance, patient outcomes); illustrate and implement clinical advances in the treatment approach to metastatic bladder, prostate and kidney cancers (knowledge, competence, performance, patient outcomes); identify contemporary controversies in the management of bladder, prostate and kidney cancers (knowledge). Educational Methods Lectures Case Presentations Panel Discussions Audience Response System Question and Discussion Sessions

3 Evaluation A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. Accreditation/Credit Designation Physicians The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME Certificates and Attendance Verification Certificates Certificates awarding AMA PRA Category 1 Credit TM or certificates documenting attendance will be distributed to participants as they depart the symposium. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form. Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations. Target Audience This conference should be of value to urologists, medical oncologists, nurses, nurse practitioners, and physician assistants. MD Anderson Organizing Committee Conference Chairmen Christopher G. Wood, MD Program Co-Chairman Professor and Vice Chairman Nizar M. Tannir, MD Program Co-Chairman Associate Professor and Vice Chairman Conference Committee Seungtaek Choi, MD Assistant Professor Radiation Oncology Gloria Curtis Senior Administrative Assistant John W. Davis, MD Assistant Professor Silvestina DeCoteau, RN, MSN, NEA-BC Nursing Program Co-Chairman Associate Director of Clinical Nursing Nursing Carol Fourtunia Senior Administrative Assistant Lisa G. Green, MSN, RN, AOCN Nurse Educator Nursing Deborah Hooker, RN, MSN, BC, ACNP Nursing Program Co-Chairman Advanced Practice Nurse Colleen Hubona Director, Multidisciplinary Programs and Projects Program Center Genitourinary Jay B. Shah, MD Assistant Professor Arlene Siefker-Radtke, MD Associate Professor Judi Williams, BS Senior Conference Coordinator CME/Conference Management

4 Program Urologic Oncology: Advances in Clinical Practice Friday, November 2, 2012 Noon Registration and General Session Lunch 12:45 pm Welcome and Opening Remarks Christopher G. Wood, MD; and Nizar M. Tannir, MD SESSION I: UROTHELIAL CANCER Session Chairs: Jay B. Shah, MD; and Arlene Siefker-Radtke, MD Superficial Disease Moderator: Jay B. Shah, MD 1:00 Basics of Superficial Disease and CIS: The University of Texas MD Anderson Cancer Center Treatment Algorithm Jay B. Shah, MD 1:10 Novel Approaches to Localized Bladder Cancer Colin Dinney, MD 1:20 Controversy: T1 High Grade Disease: BCG vs. Cystectomy BCG is the Best Therapy Ashish Kamat, MD Immediate Cystectomy is the Best Therapy Colin Dinney, MD Upper Tract Disease Moderator: Arlene Siefker-Radtke, MD 1:40 Treatment of Superficial Upper Tract Transitional Cell Carcinoma Surena Matin, MD 1:50 Role for Neoadjuvant Therapy and LND for Upper Tract Transitional Cell Carcinoma Arlene Siefker-Radtke, MD

5 2:00 Case Presentation: Superficial Bladder Cancer and Upper Tract Tumors Moderator: Jay B. Shah, MD Panelists: Colin Dinney, MD; Ashish Kamat, MD; Surena Matin, MD; and Arlene Siefker-Radtke, MD 2:30 Questions and Discussion 2:40 Break Treatment of Advanced Disease Moderator: Arlene Siefker-Radtke, MD 3:00 Robotic Cystectomy with Intracorporal Urinary Diversion John W. Davis, MD 3:10 Bladder Replacement Options O. Lenaine Westney, MD 3:20 Controversy: Extent of LND Debate Extended LND is Necessary H. Barton Grossman, MD Extended LND is Not Necessary Jay B. Shah, MD 3:40 Neoadjuvant Chemotherapy The University of Texas MD Anderson Cancer Center Treatment Paradigm Farshid Dayyani, MD, PhD 3:50 Controversy: Is There a Role for Radiation in the Curative Management of Bladder Cancer? Yes, There is a Role Andrew Lee, MD, MPH No, There is Not a Role Randall Millikan, MD, PhD 4:10 Node Positive Urothelial Cancer: When to Snip, When to Dip Arlene Siefker-Radtke, MD 4:20 Questions and Discussion 4:30 Break

6 4:45 Case Presentations in Bladder Cancer Moderator: Arlene Siefker-Radtke, MD Panelists: John W. Davis, MD; Farshid Dayyani, MD, PhD; Colin Dinney, MD; H. Barton Grossman, MD; Ashish Kamat, MD; Andrew Lee, MD, MPH; John A. Libertino, MD; Randall Millikan, MD, PhD; Jay B. Shah, MD; and O. Lenaine Westney, MD 5:30 Andrew C. von Eschenbach Lecture John A. Libertino, MD 6:15 pm Adjourn and Reception Saturday, November 3, :00 am Registration and Breakfast 8:00 Welcome and Opening Remarks Christopher G. Wood, MD; and Nizar M. Tannir, MD 8:05 Distinguished Alumnus Presentation Wassim Kassouf, MD SESSION II: KIDNEY CANCER Session Chairs: Christopher G. Wood, MD; and Nizar M. Tannir, MD Moderator: Christopher G. Wood, MD Case Presentation 74 year old WM presents with incidental finding of a 3.5 cm incidental renal mass. Co-morbidities include HTN and Type II DM. What is the Best Treatment Option? 8:30 The Case for Partial Nephrectomy Jose A. Karam, MD 8:45 The Case for Thermal Ablation Kamran Ahrar, MD 9:00 The Case for Active Surveillance Surena Matin, MD Case Presentation 55 year old WM presents with locally advanced right renal tumor with IVC thrombus up to the hepatic veins. Metastatic evaluation is negative.

7 What is the Best Treatment Option? 9:15 The Role of Adjuvant and Neoadjuvant Therapy The Role of Lymph Node Dissection in the Treatment of Kidney Cancer Christopher G. Wood, MD 9:45 Management of IVC Thrombi in Locally Advanced Renal Cell Carcinoma John A. Libertino, MD 10:00 Questions and Discussion 10:10 Break Moderator: Nizar M. Tannir, MD Case Presentation 47 year old WF presents with locally advanced left renal primary and bilateral pulmonary metastases What is the Best Treatment Option? Controversy: The Role of Cytoreductive Nephrectomy in the Era of Targeted Therapy 10:25 Upfront Cytoreductive Nephrectomy is the Standard of Care Jose A. Karam, MD 10:40 Pre-surgical Therapy is a Better Standard of Care Christopher G. Wood, MD 10:55 Immunotherapy for Metastatic Renal Cell Carcinoma: Where We Have Been and Where We are Headed Eric Jonasch, MD 11:10 Systemic Targeted Therapy in the Treatment of Metastatic Renal Cell Carcinoma: What is the Right Initial Agent, and What To do at Disease Progression? Nizar M. Tannir, MD 11:25 Stereotactic Radiosurgery for Metastatic Renal Cell Carcinoma: What are the Outcomes? Stephen Settle, MD, PhD 11:40 Questions and Discussion: Renal Case Presentations Moderators: Christopher G. Wood, MD; and Nizar M. Tannir, MD Panelists: Kamran Ahrar, MD; Eric Jonasch, MD; Jose A. Karam, MD; John A. Libertino, MD; and Surena Matin, MD

8 12:30 pm Lunch SESSION III: PROSTATE CANCER Session Chairs: Seungtaek Choi, MD; and John W. Davis, MD Moderator: John W. Davis, MD 1:15 Topic: Screening / Detection for Prostate Cancer Discussants: John W. Davis, MD; Robert B. Evans, PA-C; and William J. Graber, MD 1:45 Topic: Low Grade / Volume Prostate Cancer Treatment Options Discussants: Brian F. Chapin, MD; Andrew Lee, MD, MPH; Vikas Kundra, MD, PhD; Thomas Pugh, MD; and John F. Ward, MD 2:30 Topic: High Risk / Locally Advanced Prostate Cancer Treatment Options Discussants: Brian F. Chapin, MD; Paul Corn, MD; and Sean McGuire, MD, PhD 3:15 Break 3:30 Topic: Lymph Node Positive Prostate Cancer Discussants: Brian F. Chapin, MD; Karen Hoffman, MD; and Lance Pagliaro, MD 4:00 Topic: Recurrent / Metastatic Disease Discussants: Ana Aparicio, MD; Brian F. Chapin, MD; and Seungtaek Choi, MD 4:45 Case Presentations in Prostate Cancer Moderator: Seungtaek Choi, MD Panelists: Ana Aparicio, MD; Brian F. Chapin, MD; Paul Corn, MD; John W. Davis, MD; Karen Hoffman, MD; Lance Pagliaro, MD; and John F. Ward, MD 5:30 pm Closing Remarks and Adjourn Christopher G. Wood, MD

9 MD Anderson Faculty Kamran Ahrar, MD Diagnostic Radiology Ana Aparicio, MD Brian F. Chapin, MD Seungtaek Choi, MD Radiation Oncology Paul Corn, MD John W. Davis, MD Farshid Dayyani, MD, PhD Colin Dinney, MD Robert B. Evans, PA-C William J. Graber, MD H. Barton Grossman, MD Karen Hoffman, MD Radiation Oncology Eric Jonasch, MD Ashish Kamat, MD Jose A. Karam, MD Vikas Kundra, MD, PhD Diagnostic Radiology Andrew Lee, MD, MPH Radiation Oncology Surena Matin, MD Sean McGuire, MD, PhD Radiation Oncology Randall Millikan, MD, PhD Lance Pagliaro, MD Thomas Pugh, MD Radiation Oncology Stephen Settle, MD, PhD Radiation Oncology Jay B. Shah, MD Arlene Siefker-Radtke, MD Nizar M. Tannir, MD John F. Ward, MD O. Lenaine Westney, MD Christopher G. Wood, MD Guest Faculty Andrew C. von Eschenbach Lecture John A. Libertino, MD Chair, Institute of Lahey Clinic Medical Center Professor of Tufts University Burlington, Massachusetts Distinguished Alumni Wassim Kassouf, MD Program Director McGill Residency Assistant Professor Department of Surgery McGill University Health Center Montreal, Canada

10 Urologic Oncology: Nursing Advances in Clinical Practice Accreditation/Credit Designation Nursing Continuing Education Contact Hours will be provided. The University of Texas MD Anderson Cancer Center is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center s Commission on Accreditation. Educational Objectives After attending this educational activity, participants should be able to Describe the genitourinary anatomy in detail; Identify patients who are candidates for PSA screening according to current guidelines and the new PSA controversy; Discuss the treatment options and modalities offered to newly diagnosed prostate cancer patients through the Multidisciplinary Clinic; Identify urothelial cancer patients who are surgical candidates, discuss their post-operative care management, and describe acute post-operative complications and intervention rationales; Explain the psychological impact of urinary diversions/ostomies and discuss management; Discuss treatment modalities for renal tumor observation versus surgery and explain the rationale for both; Describe the rationale and guidelines for the GU Cancer Survivorship Program and identify the patient benefits. MD Anderson Nursing Session Faculty Reena W. Cherry, MS, PA-C Physician Assistant Silvestina DeCoteau, RN, MSN, NEA-BC Associate Director of Clinical Nursing Nursing Deborah Hooker, RN, MSN, BC, ACNP Advanced Practice Nurse Irene A. Inguillo, BSN, RN, CURN Clinical Nurse, Outpatient GU Center, Medical Oncology Lydia T. Madsen, RN, MSN, CNS Advanced Practice Nurse Robert L. Massey, PhD, RN, NEA-BC Assistant Professor Nursing William E. Osai, RN, MSN, FNP-C Advanced Practice Nurse Cynthia A. Worley, BSN, RN, CWOCN Wound Ostomy Continence Nurse Nursing

11 Nursing Session Program Friday, November 2, :30 am Registration and Continental Breakfast Poster Session 8:00 Welcome and Opening Remarks Deborah Hooker, RN, MSN, BC, ACNP Nursing Program Co-Chairman 8:05 Anatomical Review Genitourinary System Irene A. Inguillo, BSN, RN, CURN 8:15 Prostate Cancer Screening: Current Guidelines and PSA Controversies Deborah Hooker, RN, MSN, BC, ACNP 9:00 Multidisciplinary Prostate Cancer Clinic: What are the treatment options? Lydia T. Madsen, RN, MSN, CNS 9:45 Break and Poster Session 10:00 Urothelial Cancer: Candidates for Surgical Intervention Post-Operative Care and Acute Post-Operative Complications Silvestina DeCoteau, RN, MSN, NEA-BC; and Robert L. Massey, PhD, RN, NEA-BC 10:40 Psychological Impact and Management of Urinary Diversion / Ostomy Cynthia A. Worley, BSN, RN, CWOCN 11:00 Renal Tumor Treatment Modalities: Surgery vs. Observation Reena W. Cherry, MS, PA-C 11:45 Survivorship Clinic: Rationale and Benefits William E. Osai, RN, MSN, FNP-C 12:15 pm Closing Remarks and Evaluations Silvestina DeCoteau, RN, MSN, NEA-BC Nursing Program Co-Chairman

12 Registration Information Urologic Oncology: Nursing Advances in Clinical Practice On-site registration opens at 7:30 am on Friday, November 2, The conference will begin at 8:00 am and end at 12:15 pm on Friday, November 2, Those wishing to attend the general conference that begins on Friday, November 2, 2012 at 12:45 pm and ends on Saturday, November 3, 2012 at 5:30 pm must pay an additional fee of $ Please see the registration form for instructions. Urologic Oncology: Advances in Clinical Practice On-site registration opens at Noon on Friday, November 2, The conference will begin at 12:45 pm on Friday, November 2, 2012 and adjourn on Saturday, November 3, 2012 at 5:30 pm. Advance registration is encouraged as space and materials are limited. Please see the registration form for applicable fees. The full conference registration fee includes the tuition, syllabus, breakfasts, breaks, lunches, and reception. The deadline for advance registration is Friday, October 19, There are three ways to register: Mail to: CME/Conference Management Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box , Houston, TX Fax to: On-line at We accept the following forms of payment: Check (payable through U.S. banks only) Money Order Credit Cards (MasterCard, VISA, and American Express) Cash (on-site registration only) When registering online a receipt/confirmation letter will be automatically ed to the address you list on the registration form. If you register by fax or mail, a receipt/confirmation letter will be sent to you within ten working days of receipt of your fee.

13 Refund/Cancellation Policy The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before October 19, No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, , or at the phone or fax numbers given on the registration form. In case of activity cancellation, the liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. Special Assistance Contact the Department of CME/Conference Management at or toll free at if you have any special dietary or ADA accommodation needs. Accommodations A block of rooms has been reserved for conference attendees at the Houston Marriott at the Texas Medical Center, 6580 Fannin Street, Houston, Texas. Early hotel reservation is suggested. To make reservations, please call Marriott Reservations at and identify yourself as part of the Urologic Oncology MD Anderson Room Block group staying at the Houston Marriott at the Texas Medical Center. The special meeting rate is $ single or double occupancy. Please add 17% Texas State and local taxes. Reservations and deposits received after October 18, 2012 will be confirmed if space is available and at current hotel published guest room rates.

14 Ground Transportation (prices are subject to change and variable depending on location of conference) Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). Taxicabs are available at an estimated cost of $50-60, to or from William P. Hobby Airport or George Bush Intercontinental Airport. Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott at the Texas Medical Center for $27 one-way and $54 round-trip. For more information, call or toll-free at or on-line at Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott at the Texas Medical Center for $24 one-way and $48 round-trip. For more information, call or toll-free at or on-line at Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth. Photographing, audio taping and videotaping are prohibited.

15 CONFERENCE REGISTRATION th Urologic Oncology: Advances in Clinical Practice November 2-3, 2012 Nursing Session Urologic Oncology: Nursing Advances in Clinical Practice November 2, 2012 Last Name First MI Highest Degree Department (include box no.) Specialty Institution Physician: oyes ono Street City State/Foreign Country/Zip or Mail Code Daytime Phone (with area code) Cell Phone (with area code) Fax (with area code) Address Emergency Contact Phone (with area code) Charge the following: ovisa omastercard oamerican Express Credit Card Holder Name (First/Last) Credit Card Holder Billing Address & ZIP Code Credit Card Number or MD Anderson Interdepartmental Transfer (IDT) No. Expiration Date Authorized Signature REQUIRED for credit card or IDT MD Anderson Employee ID No. (REQUIRED) IDT Approver Name (First/Last) please print IDT Approver THIS IS NOT A SELF-MAILER - Address to: 7th Urologic Oncology: Advances in Clinical Practice Nursing Session Urologic Oncology: Nursing Advances in Clinical Practice Department of CME/Conference Management Unit 1381 The University of Texas MD Anderson Cancer Center PO Box , Houston, TX or fax to Make check or money order payable to: The University of Texas MD Anderson Cancer Center GENERAL CONFERENCE REGISTRATION FEES Physicians 1 Postmarked before Oct. 19, $ Postmarked after Oct. 19, $ Students/Trainees/PAs 1 Postmarked before Oct. 19, $ Postmarked after Oct. 19, $80.00 NURSE SESSION REGISTRATION FEES 1 Postmarked before Oct. 19, $ Postmarked after Oct. 19, $55.00 General Conference Fee - Nurses 1... $50.00

16 Department of CME/Conference Management - Unit 1381 The University of Texas MD Anderson Cancer Center #176700/ PO Box Houston, TX Non-Profit Org. U.S. Postage PAID Permit No Houston, TX